Trimetazidine: A review of its use in stable angina pectoris and other coronary conditions

Drugs

Volumn 58, Issue 1, 1999, Pages 143-157

  McClellan, Karen J ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Ischaemic heart disorders; Pharmacodynamics; Pharmacokinetics; Therapeutic use; Trimetazidine

Indexed keywords

ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DILTIAZEM; GLYCERYL TRINITRATE; ISOSORBIDE DINITRATE; NIFEDIPINE; NITRATE; OXPRENOLOL; PHENAZONE; PINDOLOL; PROPRANOLOL; THEOPHYLLINE; TRIMETAZIDINE;

ANGINA PECTORIS; BRADYCARDIA; CELL PROTECTION; CLINICAL TRIAL; CONSTIPATION; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEPRESSION; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG TOLERABILITY; EXERCISE; FATIGUE; GASTROINTESTINAL SYMPTOM; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE OXYGEN CONSUMPTION; HEART RATE; HEMODYNAMICS; HOMEOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; MUSCLE CRAMP; ORAL DRUG ADMINISTRATION; PAIN; REVIEW; SYSTOLIC BLOOD PRESSURE; TRANSLUMINAL CORONARY ANGIOPLASTY; VERTIGO;

ANGINA PECTORIS; ANIMALS; CORONARY DISEASE; HUMANS; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 0032812463     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958010-00016     Document Type: Review

References (64)

1. 1. Task Force of the European Society of Cardiology. Management of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997 Mar; 18: 394-413
2. 2. Knight C, Fox K. From antianginal drugs to myocardial cytoprotective agents. Am J Cardiol 1995 Aug 24; 76: 4B-7B
3. 3. Lavanchy N, Martin J, Rossi A. Préservation par la trimétazidine du potentiel énergétique du myocarde au cours de Pischémie et de la reperfusion. Etude par spectroscopie RMN du phosphore sur le coeur isolé [ín French]. Presse Med 1986 Oct 16; 15: 1758-61
4. 2+ regulation by trimetazidine during cardiac cell acidosis. Cardiovasc Drugs Ther 1988 Mar; 1: 677-86
5. 1 regulation in the rat isolated ventricular myocyte. Br J Pharmacol 1996 Mar; 117: 831-8
6. 6. Punchaut S, Goudernant J-F, Demeure R, et al. Anti-ischemic effects of trimetazidine (TMZ): 31P-and 23NA-NMR spectroscopy in the working rat heart. Servier 1998. (Data on file)
7. 7. Kiyosuc T, Nakamura S, Arita M. Effects of trimetazidine on action potentials and membrane currents of guinea-pig ventricular myocytes. J Mol Cell Cardiol 1986 Dec; 18: 1301-11
8. +-A'I'Pase activity, and overdrive hyperpolarization in guinea-pig ventricular muscles. Eur J Pharmacol 1991 Apr 3; 195: 381-8
9. 9. Allibardi S, Chierchia SL, Margonato V, et al. Effects of trimetazidine on metabolic and functional recovery of postischemic rat hearts. Cardiovasc Drugs Ther 1998; 12: 543-9
10. 10. Libersa C, Honoré E, Adamantidis M, et al. Effects of trimetazidine on a model of in vitro myocardial ischemia [in French]. Presse Med 1986 Oct 16; 15: 1765-9
11. 11. Kay L, Finelli C, Aussedat J, et al. Improvement of long term preservation of the isolated arrested rat heart by trimetazidine: effects on the energy state and mitochondrial function. Am J Cardiol 1995 Aug 24; 76: 45B-9B
12. 12. Guarnieri C, Finelli C, Zini M, et al. Effects of trimetazidine on the calcium transport and oxidative phosphorylation of isolated rat heart mitochondria. Basic Res Cardiol 1997 Apr; 92: 90-5
13. 13. Guarnieri C, Muscari C. Effect of trimetazidine on mitochondrial function and oxidative damage during reperfusion of ischemic hypertrophied rat myocardium. Pharmacology 1993 Jun; 46: 324-31
14. 14. Elimadi A, Settaf A, Morin D, et al. Trimetazidine counteracts the hepatic injury associated with ischemia-reperfusion by preserving mitochondrial function. J Pharmacol Exp Ther 1998 Jul; 286: 23-8
15. 3H]-trimetazidine binding sites involved in the regulation of the mitochondrial permeability transition pore. Br J Pharmacol 1998 Apr; 123: 1385-94
16. 16. Guarnieri C, Muscari C. Beneficial effects of trimetazidine on mitochondrial function and superoxide production in the cardiac muscle [abstract]. Cardiovasc Drugs Ther 1990 Aug; 4 Suppl. 4: 814-5
17. 17. Lopaschuk GD, Kozak R. Trimetazidine inhibits fatty acid oxidation in the heart [abstract]. J Mol Cell Cardiol 1998; 30: A112
18. 18. Sentex E, Sergiel JP, Lucien A, et al. Is the cytoproctive effect of trimetazidine associated with lipid metabolism? Am J Cardiol 1998; 82: 18K-24K
19. 19. Lopaschuk GD. Treating ischemic heart disease by pharmacologically improving cardiac energy metabolism. Am J Cardiol 1998; 82: 14K-7K
20. 20. Mody FV, Singh BN, Mohiuddin IH, et al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am J Cardiol 1998; 82: 42K-9K
21. 21. Kantor PF, Kozak R, Clanachan AS, et al. Glucose oxidation is enhanced by the anti-anginal agent trimetazidine [abstract no. 363]. Can J Cardiol 1998 Sep; 14 Suppl, F: 169F
22. 22. Maridonneau-Parini I, Harpey C. Effect of trimetazidine on membrane damage induced by oxygen free radicals in human red cells. Br J Clin Pharmacol 1985 Aug; 20: 148-51
23. 23. Catroux P, Benchckroun N, Robert J, et al. Influence of trimetazidine on deleterious effect of oxygen radical species in post-ischemic acute renal failure in the rat [abstract]. Cardiovasc Drugs Ther 1990 Aug; 4 Suppl. 4: 816-7
24. 24. Williams FM, Tanda K, Kus M. Trimetazidine inhibits neutrophil accumulation after myocardial ischaemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993 Dec; 22: 828-33
25. 25. Tritto I, Wang P, Giraldez R, et al. Trimetazidine prevents neutrophil-mediated myocardial injury in post-ischaemic rat hearts [abstract]. Eur Heart J 1997 Aug; 18 Abstract Suppl.: 53
26. 26. Camilleri JP, Joseph D. Effets de la trimétazidine (Vastarel 20 mg) sur l'infarctus expérimental du rat perfusé [abstract]. Arch Mal Coeur Vaiss 1988; 81: 371
27. 27. Catroux P, Dorian C, Harpey C, et al. Mise en évidence de l'effet protecteur de la Trimétazidine vis-á-vis de l'enzymurie induite pat clampage du pédicule rénal chez le rat. Nephrologie 1986; 7: 124
28. 28. Kober G, Buck T, Sievert H, et al. Myocardial protection during percutaneous transluminal coronary angioplasty: effects of trimetazidine. Eur Heart J 1992 Aug; 13: 1109-15
29. 29. Timour Q, Harpey C, Durr F, et al. Is the antianginal action of trimetazidine independent of hemodynamic changes? Cardiovasc Drugs Ther 1991 Dec; 5: 1043-4
30. 30. Sellier P, Audouin P, Payen B, et al. Acute effects of trimetazidine evaluated hy exercise testing. Eur J Clin Pharmacol 1987; 33: 205-7
31. 31. Lu C, Dabrowski P, Fragasso G, et al. Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998 Oct 1; 82: 898-901
32. 32. Michaelides AP, Vyssoulis GP, Bonoris PE, et al. Beneficial effects of trimetazidine in men with stable angina under beta-blocker treatment. Curr Ther Res 1989; 46: 565-76
33. 33. Passeron J. Efficacité de la trimétazidine dans Fangor d'effort stable de l'insuffisant coronarien chronique. Etude à double insu contre placebo. Presse Med 1986 Oct 16; 15: 1775-8
34. 34. Gallet M. Efficacité clinique de la trimétazidine dans l'angor d'effort stable. Etude contrôlée à double insu contre placebo. Presse Med 1986 Oct 16; 15: 1779-82
35. 35. Dalla-Volta S, Maraglino G, Della-Valentina P, et al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther 1990 Aug; 4 Suppl. 4: 853-9
36. 36. Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina: comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994 Mar; 37: 279-88
37. 37. Harpey C, Clauser P, Labrid C, et al. Trimetazidine, a cellular anti-ischemic agent. Cardiovasc Drug Rev 1989; 6 (4): 292-312
38. 38. Goupit P. Pharmacocinétique de la trimétazidine. Concours Med 1987; 109 Suppl. 36: 3447-51
39. 39. Jackson PJ, Brownsill RD, Taylor AR, et al. Identification of trimetazidine metabolites in human urine and plasma. Xenobiotica 1996 Feb; 26: 221-8
40. 40. Edeki TI, Johnston A, Campbell DB, et al. An examination of the possible pharmacokinetic interaction of trimetazidine with theophylline, digoxin and antipyrine. Br J Clin Pharmacol 1988; 26: 657P
41. 41. Szwed H, Pachocki R, Domzad-Bochenska M, et al. Efficacy and tolerance of trimetazidine in combination with a conventional antianginal drug in patients wilh stable effort angina. Diagn Treat Cardiol 1997; 4: 237-47
42. 42. Manchanda SC, Krishnaswami S. Combination treatment with trimetazidine and diltiazem in stable angina pectoris. Heart 1997 Oct; 78: 353-7
43. 43. Michaelides AP, Spiropoulos K, Dimopoulos K. Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate-propranolol in patients with stable angina. Clin Drug Invest 1997 Jan; 13: 8-14
44. 44. Levy S, Group of South of France Investigators. Combination therapy of trimetazidine with diltiazem in patients with coronary artery disease. Am J Cardiol 1995 Aug 24; 76: 12B-6B
45. 45. Brochier M, Demange J, Ducloux G, et al. Intérêt de l'association de la trimétazidine à un inhibiteur calcique dans le traitement de l'insuffisance coronarienne chronique [in French]. Ann Cardiol Angeiol Paris 1986 Jan; 35: 49-56
46. 46. Szwed H, Sadowski Z, Pachocki R, et al. Anti-ischaemic effects and tolerability of trimetazidine in coronary diabetic patients: a sub-study from TRIMPOL-I. Cardiovasc Drugs Ther. In press
47. 47. Szwed H, Sadowski Z, Pachocki R, et al. TRIMPOL-II - multicenter study. Efficacy and safety of trimetazidine in patients with stable angina pectoris under beta-blocker therapy. Preliminary results [abstract]. 8th International Symposium on Cardiovascular Pharmacotherapy; 1999 Mar 28-Apr 1; Amsterdam
48. 48. Shlyakhto EV, Vakhrameyeva IV, Nifontoff EM, et al. Chronic effects of myocardial cytoprotector trimetazidine for CAD: clinical, biochemical and echocardiographical follow-up [abstract]. Eur Heart J 1998; 19 Abstract Suppl.: 191
49. 49. Brottier L, Barat JL, Combe C, et al. Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy. Eur Heart J 1990 Mar; II: 207-12
50. 50. Belardinelli R, Purcaro A. Trimetazidine improves the contractile response of hibernating myocardium to low-dose dobutamine in ischemic cardiomyopathy [abstract no. 3727]. Circulation 1998 Oct 27; 98 Suppl: 1-709
51. 51. Fabiani JN, Ponzio O, Emerit I, et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg Torino 1992 Jul-Aug; 33: 486-91
52. 52. Vedrinne J-M, Vedrinne C, Bompard D, et al. Myocardial protection during coronary artery bypass graft surgery: a randomized, double-blind, placebo-controlled study with trimetazidine. Anesth Analg 1996 Apr; 82: 712-8
53. 53. Birand A, Kudaiberdieva GZ, Batyraliev TA, et al. Effects of trimetazidine on heart rate variability and left ventricular systolic performance in patients with coronary artery disease after percutaneous transluminal angioplasty. Angiology 1997 May; 48: 413-22
54. 54. Steg PG, Grollier G, Gallay P, et al. A randomized double-blind trial of trimetazidine as adjunetive therapy to primary PTCA for acute myocardial infarction: evidence for improved myocardial reperfusion from ST-segment analysis [abstract]. Eur Heart J 1998; 19 Abstract Suppl.: 365
55. 55. Servier. Vastarel 20: a new strategic approach to the management of coronary disease. Servier, France
56. 56. Ridker PM, Manson JE, Gaziano JM, et al. Low-dose aspirin therapy for chronic stable angina: a randomized, placebo-controlled clinical trial. Ann Intern Med 1991; 114: 835-9
57. 57. Juul-Möller S, Edvardsson N, Jahnmatz B, et al. Double-blind trial of aspirin in primary prevention of myocardial infaretion in patients with stable chronic angina pectoris. Lancet 1992; 340: 1421-5
58. 58. Abrams J. Therapy of angina pectoris with long-acting nitrates: which agent and when? Can J Cardiol 1996; 12 Suppl. C: 9C-16C
59. 59. Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf 1996; 15 (2): 91-106
60. 60. Houston MC, Hodge R. Beta-adrenergic blocker withdrawal syndromes in hypertension and other cardiovascular diseases. Am Heart J 1998 Aug: 515-23
61. 61. British National Formulary No. 35. Oxon: The Pharmaceutical Press, Mar, 1998. p562
62. 62. Packer M. Combined beta-adrenergic and calcium-entry blockade in angina pectoris. N Engl J Med 1989 Mar 16; 320: 709-18
63. 63. Fox KM, Mulcahy D, Findlay I, et al. The Total Ischaemic Burden European Trial (TIBET): effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. Eur Heart J 1996; 17: 96-103
64. 64. Savonitto S, Ardissino D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. J Am Coll Cardiol 1996 Feb; 27: 311-6